Abstracts tagged "animal models and rheumatoid arthritis"

Abstract Number: 985 • 2019 ACR/ARP Annual Meeting
Inhibition of Calcium/calmodulin-dependent Protein Kinase IV in Rheumatoid Arthritis: Dual Effect on Th17 Cell Activation and Osteoclastogenesis
Tomohiro Koga¹, Tomohito Sato ², Yushiro Endo ¹, Sosuke Tsuji ¹, Ayuko Takatani ¹, Toshimasa Shimizu ¹, Remi Sumiyoshi ¹, Takashi Igawa ¹, Shin-ya Kawashiri ¹, Naoki Iwamoto ¹, Kunihiro Ichinose ¹, Mami Tamai ¹, Hideki Nakamura ¹, Tomoki Origuchi ³, Nobuya Yoshida ⁴, Masataka Umeda ⁵, George Tsokos ⁴ and Atsushi Kawakami ⁶, ¹Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, ²Nagasaki University, Nagasaki, Japan, ³Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki
Background/Purpose: Background: CD4 + T cells are important in the pathogenesis of rheumatoid arthritis (RA), and therapies targeting the differentiation of osteoclasts are attracting attention. Calcium/calmodulin-dependent…
Abstract Number: 2900 • 2018 ACR/ARHP Annual Meeting
Impaired TCR Signaling Paves the Way for Cytokine Hyper-Responsiveness in Arthritogenic T Cells
Judith Ashouri¹, Lih-Yun Hsu¹, Dmitry Rychkov², Marina Sirota², Lisa Lattanza³, Eric Hansen³, Julie Zikherman¹ and Arthur Weiss¹, ¹Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, ³Orthopedic Surgery, University of California, San Francisco, San Francisco, CA
Background/Purpose: The inability to identify relevant arthritogenic CD4 T cells in patients and in murine disease models has limited our understanding of disease initiating events…
Abstract Number: 179 • 2016 ACR/ARHP Annual Meeting
CD11b+Gr1dimcells, Which Are Induced By GM-CSF Produced By Th17 and Group3 Innate Lymphoid Cell, May Facilitate the Progression of Pneumonitis in SKG Mice
Sho Sendo¹, Jun Saegusa¹, Takaichi Okano², Soshi Takahashi³ and Akio Morinobu¹, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Rheumatoid lung disease is a prognostic factors of rheumatoid arthritis in human. The pathogenesis and the mechanism of rheumatoid lung disease is unclear. Zymosan…
Abstract Number: 2705 • 2015 ACR/ARHP Annual Meeting
AAA-Atpase p97-HDAC6 Controlled Poly-Ubiquitin Turnover Regulates Apoptotic and Autophagy-Associated Cell Death in Arthritis
Masaru Kato¹, Kerstin Klein², Caroline Ospelt², Christoph Kolling³, Michihito Kono¹, Shinsuke Yasuda¹, Renate E. Gay⁴, Steffen Gay⁵ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Schulthess Clinic, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ⁵Center of Experimental Rheumatology, University Hospital Zurich, University Zurich, Zurich, Switzerland
Background/Purpose: The AAA-ATPase valosin containing protein (p97) and histone deacetylase 6 (HDAC6) interact with each other and are implicated in the degradation of ubiquitin-labelled proteins.…
Abstract Number: 2165 • 2014 ACR/ARHP Annual Meeting
Myeloid-Derived Suppressor Cells in Rheumatoid Arthritis: Friend or Foe?
Fanlei Hu¹, Chunqing Guo², Xiang-Yang Wang² and Zhanguo Li¹, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Department of Human and Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, VA
Background/Purpose Although myeloid-derived suppressor cells (MDSCs) have been linked to T-cell tolerance, their role in rheumatoid arthritis (RA) remains exclusive. Here, we investigated the potential…
Abstract Number: 1512 • 2014 ACR/ARHP Annual Meeting
Therapeutic Efficacy of a Novel Oral Small Molecule Macrophage Migration Inhibitory Factor [MIF] Inhibitor: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
Anderson Gaweco^1,2, Samantha Palmer², Rambon Shamilov², Caroline Stremnitzer², Michael Fisher², Gregg Crichlow², William Windsor², Ellen M. Ginzler³ and Jefferson Tilley², ¹SUNY-Downstate Medical Center, Brooklyn, NY, ²Innovimmune Biotherapeutics, Brooklyn, NY, ³Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: Macrophage migration inhibitory factor [MIF] is a cytokine secreted by activated T cells and macrophages that plays an important role in RA and autoimmune…
Abstract Number: 338 • 2014 ACR/ARHP Annual Meeting
Bombina Variegate peptide8/Prokineticin 2: A Novel Arthritis-Inducible Chemokine
Haruyasu Ito, Ken Yoshida, Kentaro Noda and Daitaro Kurosaka, Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by the joint destruction. Chemokines play important roles as monocyte and neutrophil recruiters in RA.…
Abstract Number: 2817 • 2014 ACR/ARHP Annual Meeting
Histone Deacetylase One Contributes to the Auto-Aggressive Phenotype of Rheumatoid Arthritis
Sarah Hawtree¹, Munitta Muthana¹, J. Mark Wilkinson², Anthony G. Wilson¹ and Mohammed Akil³, ¹Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ²Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, United Kingdom, ³Rheumatology Department, Sheffield South Yorkshire, United Kingdom
Background/Purpose Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease that affects synovial joints. A key characteristic of RA is hyperplasia of fibroblast-like synoviocytes (FLS)…
Abstract Number: 1792 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Chemokine Receptors CCR1 and CCR6 As Promising Therapies For Autoimmune Diseases Such As Rheumatoid Arthritis and Psoriasis
Daniel Dairaghi¹, Penglie Zhang², Manmohan Leleti², Robert Berahovich³, Karen Ebsworth³, Linda Ertl³, Shichang Miao⁴, Zhenhua Miao³, Lisa Seitz³, Joanne Tan³, Matthew Walters³, Yu Wang³, Jay Powers⁵, Thomas J. Schall⁶ and Juan C. Jaen⁷, ¹Biology, ChemoCentryx, Inc., Mountain View, CA, ²Chemistry, ChemoCentryx, Mountain View, CA, ³Biology, ChemoCentryx, Mountain View, CA, ⁴Pharmacokinetics, ChemoCentryx, Inc., Mountain View, CA, ⁵ChemoCentryx, Mountain View, CA, ⁶ChemoCentryx, Inc., Mountain View, CA, ⁷Discovery and Preclinical Development, ChemoCentryx, Inc., Mountain View, CA
Background/Purpose: Chemokines are key regulators of leukocyte activation and recruitment to sites of inflammation. Of particular relevance in rheumatoid arthritis (RA), the chemokine receptors CCR1…
Abstract Number: 1302 • 2013 ACR/ARHP Annual Meeting
Application of Cytostatic Agent Kinesin Eg5 Inhibitor Litronesib (KF89617) On Rat Adjuvant-Induced Arthritis and Mouse Type II Collagen-Induced Arthritis
Ichiro Miki¹ and Masako Uchii², ¹Fuji Research Park, Kyowa Hakko Kirin, Co., Ltd., Shizuoka, Japan, ²Fuji Research Park, Kyowa Hakko Kirin Co., Ltd., Shizuoka, Japan
Background/Purpose: Kinesins are family of motor proteins that are involved in mitosis and intracellular transport of vesicles and organelles. The mitotic kinesin, Eg5, acts…
Abstract Number: 943 • 2013 ACR/ARHP Annual Meeting
Synergism Between Granulocyte-Macrophage Colony Stimulating Factor and Interleukin-17 Causes Joint Damage Via The Production Of Interleukin-23, Receptor Activator Of NF-κB Ligand and S100A8
Annemarie E.M. Van Nieuwenhuijze¹, Fons A.J. Van de Loo², Birgitte Walgreen³, Miranda B. Bennink⁴, Monique M. Helsen³, Liduine Van den Bersselaar¹, Ian P. Wicks^5,6, Wim B. Van den Berg⁷ and Marije I. Koenders⁷, ¹Rheumatology and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Inflammation Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, Australia, ⁶Department of Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, ⁷Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Background/Purpose: T helper-17 (Th17) cells are important mediators of inflammatory diseases, and are the main pathogenic cell type in many animal models of autoimmunity. Recent…
Abstract Number: 1636 • 2012 ACR/ARHP Annual Meeting
Commensal Gut-Derived Bacteria As Therapy for Systemic Autoimmune Disease
David Luckey¹, Eric Marietta¹, Harvinder S. Luthra², Robin Patel³, Joseph A. Murray⁴, Ashutosh Mangalam¹ and Veena Taneja¹, ¹Immunology, Mayo Clinic, Rochester, MN, ²Medicine/Division of Rheum, Mayo Clinic, Rochester, MN, ³Medicine, Mayo Clinic, Rochester, MN, ⁴Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that leads to destruction of joints. Although etiology of RA is unknown, both genetic and environmental factors…
Abstract Number: 901 • 2012 ACR/ARHP Annual Meeting
Colony-Stimulating Factor (CSF) Receptor 1 Blockade Overcomes Overlapping Effects of M-CSF and Interleukin-34 On Myeloid Differentiation and Gene Expression to Reduce Inflammation in Human and Murine Models of Rheumatoid Arthritis
Samuel Garcia¹, Linda M. Hartkamp², Inge E. van Es², Haishan Lin³, Li Long³, Emma L. Masteller³, Brian R. Wong³, Paul P. Tak⁴ and Kris A. Reedquist², ¹Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Five Prime Therapeutics, Inc., South San Francisco, CA, ⁴Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: Disease activity and response to therapy in RA correlates with changes in synovial macrophage numbers and their products. M-CSF or IL-34 stimulation of their…
Abstract Number: 336 • 2012 ACR/ARHP Annual Meeting
Preclinical Development of ALX-0061, an Anti-IL-6R Nanobody^®For Therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile
Maarten Van Roy¹, Hans Ulrichts², Stefaan Rossenu², Sandy Jacobs², Sofie Poelmans³, Gert Verheyden², Michel Vierboom⁴, Bert 't Hart⁴, Judith Baumeister¹ and Josefin-Beate Holz⁵, ¹Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ²Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ³Pharmacology, Ablynx NV, Gent, Belgium, ⁴Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, ⁵Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor IL-6R. IL-6 plays an important role in the…
Abstract Number: 327 • 2012 ACR/ARHP Annual Meeting
Tolerogenic Dendritic Cells Ameliorates the Disease Severity of Murine Collagen-Induced Arthritis
Bin Ning¹, Shang-You Yang², Jianlu Wei¹, Weiming Gong¹ and Paul H. Wooley², ¹Orthopaedic Surgery, Shandong University Jinan Central Hospital, Jinan, China, ²Orthopaedic Research Institute, Via Christi Wichita Hospitals, Wichita, KS
Background/Purpose: Rheumatoid arthritis (RA) is a common autoimmune disease characterized by synovial inflammation, cartilage breakdown and bone destruction with the involvement of various types of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].